Nyxoah S.A. (NYXH) Financial Ratios
9 years of historical data (2017–2025) · Healthcare · Medical - Instruments & Supplies
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
0.93
↓-61% vs avg
5yr avg: 2.39
30Y Low1.1·High3.7
ROE
↓
-111.0%
↑-121% vs avg
5yr avg: -50.1%
30Y Low-229%·High-20%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
NYXH Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Nyxoah S.A. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $52M | $175M | $262M | $130M | $129M | $547M | — | — | — | — |
| Enterprise Value | $66M | $187M | $250M | $121M | $123M | $423M | — | — | — | — |
| P/E Ratio → | -0.51 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 4.48 | 17.49 | 57.94 | 29.85 | 41.78 | 642.29 | — | — | — | — |
| P/B Ratio | 0.93 | 3.57 | 2.31 | 1.32 | 1.07 | 3.68 | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
NYXH EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 18.70 | 55.39 | 27.80 | 39.83 | 496.95 | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — |
NYXH Profitability
Margins and return-on-capital ratios measuring operating efficiency
Nyxoah S.A. earns an operating margin of -827.8%. Operating margins have expanded from -1037.3% to -827.8% over the past 3 years, signaling improving operational efficiency. A negative ROE of -111.0% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 63.1% | 63.1% | 65.7% | 61.9% | 62.7% | 64.4% | 56.5% | — | — | — |
| Operating Margin | -827.8% | -827.8% | -1300.8% | -1037.3% | -1053.8% | -3080.0% | -16266.7% | — | — | — |
| Net Profit Margin | -899.1% | -899.1% | -1310.2% | -993.8% | -1012.5% | -3241.7% | -17746.4% | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -111.0% | -111.0% | -56.1% | -39.6% | -23.2% | -20.6% | -20.1% | -144.8% | -121.2% | -229.1% |
| ROA | -65.1% | -65.1% | -41.9% | -32.0% | -19.7% | -17.8% | -15.6% | -54.2% | -62.3% | -93.1% |
| ROIC | -76.4% | -76.4% | -46.2% | -33.3% | -35.0% | -87.7% | -65.2% | -246.0% | — | — |
| ROCE | -80.4% | -80.4% | -47.7% | -37.4% | -22.4% | -18.0% | -15.6% | -60.6% | -66.6% | -108.0% |
NYXH Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $12M ($42M total debt minus $30M cash).
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.86 | 0.86 | 0.20 | 0.13 | 0.10 | 0.08 | 0.12 | 3.64 | 0.56 | 1.16 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.25 | -0.10 | -0.09 | -0.05 | -0.83 | -0.83 | 1.16 | -1.05 | -1.07 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -51.68 | -51.68 | -30.90 | -36.82 | -125.82 | -62.83 | -56.69 | -12.41 | -310.66 | -278.30 |
NYXH Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.25x means Nyxoah S.A. can comfortably meet its short-term obligations, though there is limited excess liquidity. The current ratio has declined from 4.73x to 1.25x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.25 | 1.25 | 4.56 | 4.73 | 6.72 | 12.10 | 14.70 | 1.82 | 8.77 | 6.11 |
| Quick Ratio | 1.16 | 1.16 | 4.34 | 4.50 | 6.66 | 12.07 | 14.69 | 1.82 | 9.14 | 6.44 |
| Cash Ratio | 0.98 | 0.98 | 3.97 | 4.00 | 6.36 | 11.71 | 14.42 | 1.34 | 8.41 | 5.78 |
| Asset Turnover | — | 0.08 | 0.03 | 0.04 | 0.02 | 0.00 | 0.00 | — | — | — |
| Inventory Turnover | 0.79 | 0.79 | 0.33 | 0.50 | 1.30 | 0.88 | 0.45 | — | — | — |
| Days Sales Outstanding | — | 281.26 | 273.04 | 472.37 | 264.05 | 1076.15 | 10640.63 | — | — | — |
NYXH Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Nyxoah S.A. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — |
| Shares Outstanding | — | $38M | $33M | $28M | $26M | $24M | $18M | $21M | $21M | $21M |
Peer Comparison
Compare NYXH with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 NYXHYou | $52M | -0.5 | — | — | 63.1% | -827.8% | -111.0% | -76.4% | — |
 INSP | $1B | 8.7 | 17.8 | 15.7 | 85.4% | 5.6% | 19.8% | 6.0% | 0.5 |
 LIVN | $4B | -17.8 | 17.4 | 25.2 | 67.7% | 14.4% | -19.2% | 11.5% | 2.0 |
 AVAV | $9B | 110.1 | 104.4 | — | 39.4% | 5.0% | 5.1% | 3.6% | 0.8 |
 NVCR | $2B | -14.6 | — | — | 74.5% | -23.5% | -38.9% | -16.4% | — |
 ELMD | $308M | 43.2 | 26.5 | 27.7 | 78.1% | 15.4% | 17.2% | 26.1% | 0.0 |
 RMTI | $25M | -4.2 | — | — | 16.9% | -6.8% | -15.3% | -11.0% | — |
 MDT | $103B | 22.2 | 14.7 | 19.9 | 65.3% | 17.8% | 9.4% | 6.0% | 3.2 |
 ABT | $153B | 11.5 | 16.0 | 24.1 | 50.8% | 16.3% | 30.9% | 9.9% | 1.5 |
 BSX | $70B | 24.2 | 21.5 | 19.1 | 69.0% | 19.8% | 12.4% | 8.8% | 3.3 |
 SYK | $120B | 37.2 | 21.4 | 27.9 | 64.0% | 19.5% | 15.1% | 11.4% | 2.4 |
| Healthcare Median | — | 22.9 | 14.4 | 18.9 | 63.9% | -4.3% | -32.6% | -11.4% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 9 years · Updated daily
What if you invested $1,000 in NYXH 10 years ago?
Total return calculator · dividends reinvested
Calculate ReturnsHow much would $100/month in NYXH be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs NYXH Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationNYXH vs INSP — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Inspire Medical Systems, Inc..
Compare NowNYXH — Frequently Asked Questions
Quick answers to the most common questions about buying NYXH stock.
What is Nyxoah S.A.'s P/E ratio?
Nyxoah S.A.'s current P/E ratio is -0.5x. This places it at the 50th percentile of its historical range.
What is Nyxoah S.A.'s ROE?
Nyxoah S.A.'s return on equity (ROE) is -111.0%. The historical average is -85.1%.
Is NYXH stock overvalued?
Based on historical data, Nyxoah S.A. is trading at a P/E of -0.5x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Nyxoah S.A.'s profit margins?
Nyxoah S.A. has 63.1% gross margin and -827.8% operating margin.